On Nov 16, Dr Reddy's Laboratories announced the launch of a wearable therapy device for the drug-free treatment of migraine. The US Food and Drug Administration (USFDA) has approved the product Nerivio, as reported by the Hyderabad-based drug maker in a regulatory filing.
Nerivio is a non-invasive device that requires a prescription and is designed for the acute and preventive treatment of migraine in individuals aged 12 and older.
The device should be worn on the upper arm and used within 60 minutes of the start of a headache for treating acute migraine or every other day for preventing migraine, according to the drug manufacturer.
"The rollout of Nerivio marks our entry into digital therapeutics. It is an area that is seeing increasing adoption by physicians as well as patients due to its potential to reduce pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said.
He added that the company believes the product fulfills a legitimate, unmet clinical need for migraine patients.
Dr. Reddy's has recently entered into an exclusive agreement to commercially market and distribute Nerivio in Germany, Austria, Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Spain, Sweden, Switzerland, and the United Kingdom.
.jpg "The Role of CAE in Ensuring Safety and Compliance in Automotive Design")
